IDEAYA Announces Stock Option Grants Under Inducement Plan
IDEAYA Biosciences, (“IDEAYA”) a company developing precision medicine and oncology drugs, announced today it has granted stock options to a newly hired employee. The announcement was made by the Compensation Committee of IDEAYA on June 26, 2025.
The stock options granted were non-qualified stock options to purchase up to 95,600 shares of the common stock of IDEAYA. The stock option grant was made under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (the “2023 Inducement Plan”) to comply with and in accordance with Nasdaq Listing Rule 5635(c)(4) to hire new employees.
Nasdaq Listing Rule 5635(c)(4) allows securities that represent stock awards (“Awards”) be granted to individuals that have not been employed by the Company, or have not been employees after a period of non-employment. ; and may also consider such Award a material inducement for employment and is approved outside the Company’s existing equity compensation plans.
The options provided by Grant were for an exercise price of $22.29 per share (which was the closing price of IDEAYA’s common stock listed on the Nasdaq Global Select Market on the date of the grant). The total term of the options is 10 years from the grant date.
The options will vest over a four year period. 25% of the shares will vest after one year from the date that vesting begins, and the remaining 75% will vest monthly over the next three years. All vesting is contingent on continued employment at IDEAYA
IDEAYA noted that this continued effort to design and offer equity participation options – continues in an effort to attract talented people working in biotech and/or drug development for cancer. IDEAYA has continued to focus on attracting and developing strong people by offering competitive benefits and a long term equity incentive
IDEAYA is focused on discovering and developing a new generation of cancer therapies utilizing a precision approach that target genetic mutations. IDEAYA has multiple investigational drugs for multiple human tumor types in their pipeline
The 2023 Inducement Plan is only for new hires, and not existing employees. It is a part of IDEAYA’s long term vision to build a science-first company with talented people
This new stock option grant continues to demonstrate company’s plan to support strategic hiring and with retention in a competitive sector like biotechnology.
____________________________________________________________________________________________________
Latest Stories
Ericsson Named Top Sustainable Corporate Citizen in Canada
